Skip to Content

Harmony Biosciences Holdings, Inc.

Company NameHarmony Biosciences Holdings, Inc.
Stock SymbolHRMY

On March 28, 2023, Scorpion Capital published a report alleging, among other things, that Harmony’s narcolepsy drug, Wakix, has “alarming toxicity,” “no efficacy,” is based on “sham patents,” and “scam clinical trials,” and has been “pushed via false advertising and a vast off-label and physician kickback scheme.”

On this news, Harmony’s share price fell $10.70 per share, or 25.8%, to close at $30.80 per share on March 28, 2023, thereby injuring investors. 

Submit Your Information

If you suffered a loss on your Harmony Biosciences Holdings, Inc. investments or would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below. Please note that submission of this form does not by itself form an attorney-client relationship nor does filing out this form mean you have joined any lawsuit.

Shares Purchased

Number of SharesBuy DatePrice Per ShareAdd

Shares Sold

Number of SharesSell DatePrice Per ShareAdd